Not yet recruitingPhase 1NCT06461676
Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)
Studying Hypoplastic left heart syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emory University
- Principal Investigator
- William Mahle, MDEmory University
- Intervention
- Ventrix Bio Extracellular Matrix(drug)
- Enrollment
- 12 target
- Eligibility
- 1 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Children's Healthcare of Altanta, Atlanta, Georgia, United States
Collaborators
Ventrix, Inc. · University of California, San Diego
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06461676 on ClinicalTrials.govOther trials for Hypoplastic left heart syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06342999Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart SyndromeMauro H. Schenone
- ACTIVE NOT RECRUITINGPHASE2NCT04925024Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.Longeveron Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03779711Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart SyndromeTimothy J Nelson, MD, PhD
- RECRUITINGPHASE3NCT02781922Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)Metcela Inc.
- RECRUITINGNCT02852031National Collaborative to Improve Care of Children With Complex Congenital Heart DiseaseChildren's Hospital Medical Center, Cincinnati